This document reports on current conditions and future prospects in the
markets for generic and innovative drugs in the Eastern European countries of
Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria.
It presents data describing the current values of generic and innovative
drugs segments in each country and analysis of the effects of regulation
on the conduct of business in this market - specifically those pertaining to
pricing, reimbursement processes, data exclusivity and patent
This publication also offers in-depth profiles of companies that
participate in generic and innovative drug development and manufacturing in
Central European markets and contains forecasts for market development
Bolster your market knowledge on a wide variety of topics
From reimbursement processes to market share of generic and innovative drugs,
this report addresses a variety of important issues:
- Segment value of generic drugs and innovative medicines from 2009-2014 in
each of the six highlighted Central European countries
- Size of the generic drugs segments in Poland, Romania, Slovakia, the Czech
Republic, Hungary and Bulgaria, growth expectations to 2018
- Innovative medicines segment - size and development forecasts for markets
in each country from 2009-2018
- Market share of each country's generic and innovative drug industry in
relation to overall pharmaceutical sectors
- Planned changes to the content of reimbursement lists in each country
- Existing reimbursement processes in each of the six CE countries
- Pricing rules for all types of generic and innovative medications,
regardless of eligibility for reimbursement
- Average drug mark ups and rates as governed by regulations
- Medical professional and patient views on the use of generic drugs and
- Upcoming modifications in store for the markets in each country
- New alterations to medication reimbursement programs in each country
- Significant recent changes and future forecasts for each country's
- Data exclusivity, patent expiration dates and SPCs (supplemental
protection certificates) - roles in the generic and innovative drug markets in
- The largest generic and innovative drug manufacturers operating in the
Central European markets
- Top selling generic and innovative drugs in each country.
Our clients ask questions. PMR supplies answers
PMR market intelligence reports are compiled with our clients' needs
for information in mind. Here is a selection of questions answered in
Generic and innovative drugs market in Central Europe 2014:
- What are the most recent value assessments of the generic and
innovative drug market in Central Europe from 2009-2018?
- In which of the six countries addressed in this document is the generic
drug market expected to grow fastest during 2014-2018?
- Which country will see the fastest growth in its innovative drug
market from 2014-2018?
- What are the opinions of medical professionals and patients with
regard to the use of generic and innovative drugs in each of the six CE
countries considered in this report?
- Which regulations in each country govern drug prices and
- How are medications reimbursed in each of these six CE countries?
- How will reimbursement procedures be altered by changes in
regulation over the period 2014-2018? How will these changes affect the
- How have recent regulations influenced the Central European markets
for generic drugs and innovative therapies?
- What are the specific patent expiry periods for Poland, Romania,
Slovakia, the Czech Republic, Hungary and Bulgaria?
- According to sales data, which products are the top sellers in
Central European countries?
- Which companies are the largest generic and innovative drug
manufacturers and producers in the Central European market?
Consult this report for detailed comparison, evaluation and forecasts for
- Generic and innovative drug market conditions in Poland, Romania,
Slovakia, the Czech Republic, Hungary and Bulgaria
- Market results of upcoming economic and regulatory changes in each
country to 2018 and analysis of their influence on generic and innovative
- Reimbursement procedures and pricing regulations in effect in each
- The generic and innovative drug industries in each country,
gathered and presented in a convenient format for a single, affordable price.
This report is a key source of information, analysis and forecasts for
- Businesses that produce and distribute generic and innovative drugs and
therapies for sale in Poland, Romania, Slovakia, the Czech Republic,
Hungary and Bulgaria
- Companies considering participation in one or more CE pharmaceutical
- Business consultants, market analysts and research specialists
- Government, educational and research institutes
- Banking, brokerage and investment professionals
- Commerce and trade organisations related to the pharmaceutical industry.
The information supplied in this report can be used to
- Plan and execute a seamless market entry strategy
- Build and/or make revisions to a corporate portfolio of products
- Analyse the regulatory environments in the generic and innovative drug
markets in Poland, Romania, Slovakia, the Czech Republic, Hungary and
- Evaluate potential for expansion in the overall Central European market
and in each of the included countries
- Respond to additions and deletions to drug reimbursement lists in each
- Compile accurate predictions for market development in the entire generic
drugs market in CE and in each included country
- Compile accurate predictions for market development in the entire
innovative drugs market in CE and in each included country.
Market commentary by expert
“In the past, the most substantial increases in the generic and
innovative subgroups were recorded in Romania and Bulgaria. This is because
these countries are, in general, the least developed (the least saturated)
among those analysed. At the other end of the scale are Poland and Hungary, as
the governments in both countries implemented very severe cost-containment
policies - the Reimbursement Act in Poland and the Szell Kalman Plan in
Hungary. These were more harmful for the innovative drugs subgroup. The
policies also had a severe effect on innovative drugs trade in Slovakia, where
innovative drugs account for a substantial proportion of the market but where
some pro-generic mechanisms have recently been introduced, e.g. a new
reference pricing system and the API prescription.” Monika
Stefanczyk, Head Pharma & Healthcare market Analyst.